ADMA Biologics Inc (ADMA)

Debt-to-assets ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	101,326	131,074	130,847	130,594	142,026	140,312	144,301	142,833	141,366	139,811	138,423	94,866	94,363	93,877	93,413	92,969	97,044	96,574	96,129	68,291
Total assets	US$ in thousands	390,618	376,399	350,875	329,182	348,997	343,027	340,788	348,461	300,558	296,932	308,032	276,253	238,640	232,814	235,667	207,673	189,976	191,542	210,524	127,091
Debt-to-assets ratio		0.26	0.35	0.37	0.40	0.41	0.41	0.42	0.41	0.47	0.47	0.45	0.34	0.40	0.40	0.40	0.45	0.51	0.50	0.46	0.54

September 30, 2024 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $101,326K ÷ $390,618K
= 0.26

The debt-to-assets ratio of ADMA Biologics Inc has exhibited some fluctuations over the past few years, ranging from 0.26 to 0.54. This ratio represents the proportion of the company's total debt relative to its total assets. A lower ratio indicates that the company relies less on debt to finance its operations and investments, while a higher ratio suggests a greater dependency on debt.

From December 2019 to December 2020, the debt-to-assets ratio increased steadily from 0.45 to 0.51, indicating a higher level of debt relative to assets during this period. Subsequently, the ratio slightly decreased to 0.40 by March 2021 and remained relatively stable at around 0.40 for the following quarters up to September 2022.

From September 2022 to September 2024, the ratio fluctuated within the range of 0.26 to 0.47, with the lowest ratio recorded in September 2024 at 0.26. This decreasing trend in the debt-to-assets ratio over the recent quarters could imply either a reduction in total debt or an increase in total assets relative to previous periods.

Overall, a decreasing debt-to-assets ratio can indicate a healthier financial position for ADMA Biologics Inc, as it suggests a lower reliance on debt to support its operations and investments. However, it is important to consider the specific circumstances of the company and industry benchmarks when interpreting this ratio.